Contract 75F40122C00154
Brigham & Womens Hospital Inc · Department Of Health And Human Services · September 27, 2022
Brigham & Womens Hospital Inc was awarded a federal contract by Department Of Health And Human Services (Food And Drug Administration) on September 27, 2022 for $2.03 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Silver Spring, MD. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on September 11, 2025.
Contract details
- PIID
- 75F40122C00154
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Basic Research
- Place of performance
- Silver Spring, MD
- First action
- September 27, 2022
- Latest action
- September 11, 2025
Description
NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 27, 2026.
Modification timeline
-
September 11, 2025Mod P00004 · Other Administrative Action$2.71M
-
September 27, 2022Base awardDESIGN A TWO-STAGE PROCESS FOR USING RWE TO SUPPORT LABELING EXPANSIONS FOR EFFECTIVENESS CLAIMS THAT IS ALIGNED WITH REGULATORY REQUIREMENTS/DEMONSTRATE AND EMPIRICALLY TEST THE PROCESS WITH HISTORIC…$2.71M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75F40122C00154?
Contract 75F40122C00154 is a federal contract awarded to Brigham & Womens Hospital Inc by Department Of Health And Human Services on September 27, 2022 for $2.03 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 1 time since the base award.
Who won contract 75F40122C00154?
Brigham & Womens Hospital Inc won contract 75F40122C00154 from Department Of Health And Human Services.
How much is contract 75F40122C00154 worth?
Contract 75F40122C00154 has obligated $2.03 million to date, with a total potential value of $2.71 million if all options are exercised.